AAN 2017

May 5, 2017May 5, 2017

Burden of Multiple Sclerosis Relapses Is Underappreciated, Study Says

News

The burden of moderate-to-severe relapses in multiple sclerosis (MS) patients is underappreciated, according to a study sponsored by the pharmaceutical company Mallinckrodt. Researchers discussed the findings at ... Read more

May 4, 2017May 4, 2017

Cladribine Tablets Reduce Risk of MS Progression and Relapse, Clinical Trial Shows

News

Cladribine tablets reduce the risk of disability progression and relapse in patients with relapsing multiple sclerosis (MS), the CLARITY clinical trial indicates. The treatment was also ... Read more

May 2, 2017May 2, 2017

Remyelination Candidate Opicinumab Failed in Phase 2 Trial in MS, But Biogen Won’t Give Up

News

Although a Phase 2b trial of the remyelination drug candidate opicinumab (also known as anti-LINGO-1 and BIIB033) failed to meet its primary goal of improving disability in ... Read more

April 28, 2017April 28, 2017

Siponimod Slows Progression of MS Disability, Phase 3 Clinical Trial Shows

News

Siponimod slows the progression of multiple sclerosis patients’ disability, a Phase 3 clinical trial indicates. The therapy reduced the risk of disability progression in patients with secondary ... Read more

April 28, 2017April 28, 2017

Lemtrada Might Outperform Ocrevus in Preventing MS Relapses, Italian Researchers Say

News

Lemtrada (alemtuzumab) may be more effective in preventing relapses in multiple sclerosis patients than the newly approved Ocrevus (ocrelizumab), according to a study presented April 28 at the ... Read more

April 27, 2017April 27, 2017

Genentech Highlights Rapid Actions of MS Therapy Ocrevus at AAN Meeting

News

Within the first two months of treatment, Ocrevus (ocrelizumab) reduced relapses in multiple sclerosis (MS) patients by more than half compared to those on Rebif, and ... Read more

April 26, 2017April 26, 2017

Sanofi Genzyme to Present New Data on MS Treatments Lemtrada and Aubagio

News

Sanofi Genzyme will present new results on follow-up studies of its products Lemtrada (alemtuzumab) and Aubagio (teriflunomide), both of which have been approved for the treatment ... Read more

April 24, 2017April 24, 2017

ATA188, Which Kills B-Cells Targeting Epstein-Barr Virus, Shows Promise as MS Treatment

News

An investigational treatment called ATA188 that wipes out B-cells targeting the Epstein-Barr virus (EBV) has shown promise as a multiple sclerosis treatment, a Phase 1 clinical trial ... Read more

April 20, 2017April 20, 2017

Teva to Discuss MS and Huntington’s Therapies at Premier Neurology Conference

News

Teva Pharmaceutical Industries will discuss two of its multiple sclerosis therapies, one that reduces relapses and one that appears to protect nerve structure, at a premier ... Read more

April 20, 2017April 20, 2017

AAN Annual Meeting Offers First Ocrevus Data Update Since MS Therapy’s Approval by FDA

Faith of the Mustard Seed - a Column by Debi Wilson, News

New data on the recently approved multiple sclerosis (MS) drug Ocrevus (ocrelizumab) will be presented at the upcoming American Academy of Neurology (AAN) Annual Meeting 2017, ... Read more

April 19, 2017April 19, 2017

Sanofi Genzyme to Discuss Three Multiple Sclerosis Therapies at Boston Event

News

Sanofi Genzyme will discuss three of its multiple sclerosis therapies at the American Academy of Neurology annual meeting in Boston, April 22-28. The presentations will cover two approved treatments ... Read more

Pin It on Pinterest